LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) — Highlights: Kabir Nath appointed as Chief Executive Officer Phase III program submitted to FDA and under review COMP360 phase II study in anorexia nervosa launched Cash position at 30 June 2022 of $207.2 million Conference call today at 8:00am ET (1:00pm UK) COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to…


Previous articleMindMed to Participate in the Canaccord Genuity 42nd Annual Growth Conference
Next articleMindMed Board of Directors Approves Reverse Share Split